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Acute myeloid leukemia (AML) patients rarely have long first
remissions (LFRs; >5 y) after standard-of-care chemotherapy,
unless classified as favorable risk at presentation. Identification of
the mechanisms responsible for long vs. more typical, standard
remissions may help to define prognostic determinants for chemo-
therapy responses. Using exome sequencing, RNA-sequencing,
and functional immunologic studies, we characterized 28 normal
karyotype (NK)-AML patients with >5 y first remissions after che-
motherapy (LFRs) and compared them to a well-matched group of
31 NK-AML patients who relapsed within 2 y (standard first remis-
sions [SFRs]). Our combined analyses indicated that genetic-risk
profiling at presentation (as defined by European LeukemiaNet
[ELN] 2017 criteria) was not sufficient to explain the outcomes of
many SFR cases. Single-cell RNA-sequencing studies of 15 AML
samples showed that SFR AML cells differentially expressed many
genes associated with immune suppression. The bone marrow of
SFR cases had significantly fewer CD4+ Th1 cells; these T cells
expressed an exhaustion signature and were resistant to activa-
tion by T cell receptor stimulation in the presence of autologous
AML cells. T cell activation could be restored by removing the AML
cells or blocking the inhibitory major histocompatibility complex
class II receptor, LAG3. Most LFR cases did not display these fea-
tures, suggesting that their AML cells were not as immunosuppres-
sive. These findings were confirmed and extended in an
independent set of 50 AML cases representing all ELN 2017 risk
groups. AML cell–mediated suppression of CD4+ T cell activation
at presentation is strongly associated with unfavorable outcomes
in AML patients treated with standard chemotherapy.
acute myeloid leukemia j immunosuppression j checkpoints j
chemotherapy j cancer genomics
A normal karyotype (NK) is the most common cytogeneticfinding in acute myeloid leukemia (AML) cells at presen-
tation (NK-AML), and has long been associated with an inter-
mediate risk for relapse (1). Although most NK-AML patients
achieve a complete remission following standard induction che-
motherapy (2, 3), the majority of patients experience relapse
within 2 y, and fewer than 10% remain in remission beyond 5 y
without an allogeneic transplant (4). Refinements introduced
with the European LeukemiaNet (ELN) 2017 criteria (presence
or absence of mutations in NPM1, FLT3-ITD, ASXL1, RUNX1,
TP53, or biallelic CEBPA mutations) have helped to reclassify
some NK-AML patients into the favorable- or adverse-risk group
categories. However, the mutational heterogeneity of NK-AML,
combined with our limited understanding of the biological conse-
quences deriving from the interplay among mutations, still poses
a major challenge for risk stratification at presentation, and for
postremission treatment decisions (5, 6).
The genetic and epigenetic characteristics of NK-AML
patients with very long first remissions (LFRs) have not been
defined, and it is not clear whether these patients are living free
from disease, or whether they harbor “dormant” AML cells that
may be held in check by immune surveillance or cell-intrinsic
mechanisms. Predictive algorithms for identifying these very
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long responders at presentation do not yet exist, but clearance of
all AML-associated mutations assessed after induction chemo-
therapy is strongly associated with prolonged relapse-free sur-
vival (RFS) and overall survival (OS) (7–12). Persistent ancestral
clones have been detected in patients in complete morphologic
remission within the first 2 to 3 y after treatment (13, 14), but
similar studies of patients with very LFRs have not yet been
described.
Most published AML studies have justifiably focused on the
mechanisms responsible for treatment failure. However, the
reasons for chemotherapy successes are underexplored, even
though they hold the potential to uncover determinants that
are especially important for excellent outcomes that might be
identifiable at presentation. To address this, we have studied
two well-matched groups of NK-AML patients that were
selected retrospectively for dramatically different outcomes
after chemotherapy (long vs. standard first remissions, [SFRs]).
In this study, we show that the outcomes of AML patients are
not only related to their mutational status, but also to an immu-
nosuppressive phenotype of AML cells at presentation (or lack
thereof), a finding that was predicted 50 y ago by Freireich and
colleagues (15) and extended in this report.
Methods
Patient Selection. All clinical data are available in the SI Appendix, sections A
and B. NK-AML patients were selected for this study because their outcomes
are highly variable and still difficult to predict at presentation. We defined
LFRs as lasting more than 5 y to ensure the durability of treatment responses,
which increases the chance of identifying robust biomarkers associated with
excellent responses. The comparator set of SFRs were defined as having an ini-
tial relapse within 2 y of presentation, since ∼70% of NK-AML cases relapse
within 2 y. We did not use the ELN 2017 criteria to select the initial sample sets
for the study, since many of the patients were treated before gene testing for
common AMLmutations was routinely performed, and it did not guide thera-
peutic decisions. We required the following inclusion criteria for all patients:
1) morphologically documented de novo AML with adequate bone marrow
(BM) and matched control (skin) DNA for sequencing studies, 2) at least 18 y
of age, 3) NK of AML cells at presentation, 4) received “7+ 3” (or similar var-
iants) for induction chemotherapy, and 5) received high or intermediate-dose
AraC as the primary consolidation therapy (i.e., no allogeneic transplant in
first remission). For the LFR cases, the initial remission had to last at least 5 y.
For the SFR cases, patients either had a morphologically documented relapse
occurring within 2 y of starting therapy (28 patients) or primary refractory dis-
ease with 7+ 3 (3 patients), prior to any form of transplant (none of these
patients were transplanted in first remission).
To identify the LFR samples for study, 1,579 cases were screened from our
AML collection atWashington University in St. Louis, and 19 cases meeting all
criteria were identified (1.2%). Nine additional LFR cases matching the above
criteria were obtained after screening 846 NK-AML samples (1.06%) at the
Alliance collection housed at The Ohio State University (but matched normal
DNA and RNA was not available for these samples). Thirty-one well-matched
NK-AML cases with SFRs were selected as comparators. Post hoc analyses
confirmed that there were no significant differences in age, sex, BM blast per-
centage at diagnosis, karyotype, or induction/consolidation treatments
between LFR and SFR patients. Samples were acquired as part of studies that
were approved by the Human Research Protection Office at both institutions.
All the patients provided written informed consent that included explicit per-
mission for genetic studies, under Institutional Review Board–approved pro-
tocols (#201011766 for Washington University and CALGB/Alliance 9665
[NCT0089922] and 20202 [NCT00900224] for samples obtained from The Ohio
State University).
Survival Analysis. OS was defined as the time from diagnosis to death.
Patients who died in remission were censored at the time of death. RFS was
defined as the time from diagnosis to the first AML relapse or death from leu-
kemia, whichever occurred first. Patients who were alive and disease-free
were censored at last follow-up. Thirteen of 50 cases in the extension cohort
who were transplanted in first remission were censored at the time of trans-
plant. The distributions of OS or RFS between different groups were described
using Kaplan–Meier product limit methods and compared by a log-rank test.
Survival curves were visualizedwith GraphPad Prism (v9.0.2).
Molecular, Immunologic, and Statistical Analyses. DNA, RNA, and viably cryo-
preserved cells were obtained from the BM aspirates of normal donors or
AML patients at presentation or at various time points during remission. The
LFR and SFR samples that were used for sequencing and functional studies are
listed in the SI Appendix. For details regarding T cell activation studies, flow
cytometry, cell culture, sequencing, bioinformatic, and statistical analyses,
refer to the SI Appendix.
Results
Mutational Spectrum of NK-AML Cases with LFRs vs. SFRs. The clin-
ical characteristics of the 28 LFR and 31 SFR cases are summa-
rized in Table 1 and detailed in Dataset S1. All patients had an
NK defined by standard cytogenetics, and received standard-of-
care induction chemotherapy and consolidation, as detailed in
Patient Selection. At the time of this writing, none of the LFR
patients from Washington University in St. Louis had relapsed
(range 5.8 to 19+ y, median follow-up 9.5 y). The two groups
were comparable in terms of age, sex, percentage of BM blasts,
and white blood cell (WBC) counts at diagnosis (Table 1). The
Kaplan–Meier distribution of RFS and OS of the LFR and
SFR cases is shown in Fig. 1 A and B). The mutational land-
scape of these cases was defined by sequencing the exomes
from the presentation BM samples from all cases. Matched
normal (skin) samples were available for the 19 LFR and 31
SFR cases banked at Washington University in St. Louis.
Somatic mutation status was inferred for the nine Alliance sam-
ples by limiting mutation calling to known, recurrently mutated
AML genes (16) (Fig. 1C and Dataset S2).
Using these data, we classified patients according to the ELN
2017 genetic risk categories (Fig. 1C, Table 1, and Dataset S1).
Table 1. Clinical characteristics of SFR vs. LFR patients
SFR (n = 31) LFR (n = 28) P value
Age at diagnosis (y) 0.93
Median 51 55
Range 21–76 19–71













ELN category, n (%)
Favorable 14 (45) 26 (93) <0.001
Intermediate 15 (48) 1 (3.5) <0.001
Adverse 2 (8) 1 (3.5) 1
Occurrence of mutation, n (%)
NPM1 17 (54.8) 24 (85.7) 0.01
DNMT3A 14 (45.2) 11 (39.3) 0.79
FLT3-ITD 14 (45.2) 5 (17.9) 0.03
Other FLT3 5 (16.1) 6 (21.4) 0.74
MYC 1 (3.2) 6 (21.4) 0.05
NRAS 5 (16.1) 11 (39.3) 0.08
WT1 6 (19.4) 3 (10.7) 0.48
TET2 4 (12.9) 3 (10.7) 1
PTPN11 2 (6.5) 5 (17.9) 0.24
IDH1 4 (12.9) 1 (3.6) 0.36
IDH2 3 (9.7) 3 (10.7) 1
CEBPA 4 (12.9) 3 (10.7) 1
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The ELN criteria classified 26 of the 28 (93%) LFR cases as
favorable risk, 1 of 28 (3.5%) as intermediate risk, and 1 of 28
(3.5%) as adverse risk. For the 31 SFR cases, 14 of 31 cases
(45%) were classified as favorable risk (median RFS 301 d), 15
(48%) were classified as intermediate risk (median RFS 195 d),
and 2 cases (8%) were classified as adverse risk by ELN criteria
(median RFS 330 d). Kaplan–Meier plots for the ELN-classified
SFR cases are shown in SI Appendix, Fig. S1. The fact that
nearly half of the SFR patients were classified as favorable risk
by ELN criteria suggested that other factors must play a role in
the fates of these patients.
Evaluation of Persistent Molecular Disease in LFR Cases. For eight
of the LFR cases, we had access to remission samples obtained
506 to 1,299 d after presentation. We performed error-corrected
sequencing (sensitivity of 4 AML cells in 10,000 total cells) of the
presentation and remission samples, targeting 5 to 18 known
somatic variants per case (17) (Dataset S3). For seven of the
eight cases, no AML-associated mutations could be detected in
any remission sample (Fig. 1D). In one case (868442), a
DNMT3AR882H and an IRS2D106Y mutation persisted in remis-
sion, suggesting that the patient retained a preleukemic, ancestral
clone. To increase the detection sensitivity of persistent AML
cells to ∼1 in 100,000 (0.001%), we performed digital-droplet
PCR for a single founding clone mutation (for which commercial
reagents were available) for five patients in remission; no persis-
tent AML cells bearing these mutations were detected in any of
these samples (SI Appendix, Fig. S2).
RNA-Sequencing Analyses of SFR vs. LFR Cases. Because bulk
RNA-sequencing cannot accurately define the expression patterns
of cellular subsets in AML samples, we performed single-cell
RNA-sequencing (scRNA-seq) of unfractionated BM from the
presentation samples of eight LFR and seven SFR cases that
were chosen based on high cellular viability (>50%) in available
cryovials; the two sets had comparable fractions of myeloblasts
based on BM aspirates flow cytometry at diagnosis (mean for
LFR 71.1% vs. SFR 66.3%, P = 0.51). In addition, whole BM
and CD34+ flow-sorted cells were evaluated from two healthy
donors (ages 33 and 36 y). SI Appendix, Fig. S3 A and B display
Uniform Manifold Approximation and Projection (UMAP) pro-
jections of normalized expression data from all cells, labeled by
cell type (18) and sample, respectively. Nonmalignant cells, such
as immune cells and erythroid cells, formed common clusters con-
taining cells from all 17 samples. For each AML sample, we iden-
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Fig. 1. Clinical and genomic features of AML patients at presentation and in remission. (A) RFS and (B) OS curves for NK-AML patients who were treated
with chemotherapy only for induction and consolidation. The blue line represents the LFR cases (n = 28) and the red line the SFR cases (n = 31). (C) The
mutational landscape and the ELN classification for each case. Each column represents a patient, and each row represents a gene that is mutated in at
least one of these cases. Every case had one or more recognized AML driver mutations, with a median of 11 (range 1 to 37) protein-altering somatic
mutations per case in the Washington University in St. Louis samples. Color indicates the type of mutation, as specified in the legend. Cases with a high
FLT3-ITD allelic ratio are indicated by the gray triangle in the figure. Blue bars at left indicate the mutation frequency in the sample set. (D) Clearance
plots displaying the variant allele frequencies (VAFs) of recurrently mutated AML genes, plotted at presentation (day 0) and at available time points dur-
ing clinically defined remissions (days), assessed with error-corrected sequencing. The average coverage of all variants for the remission samples was
3,042×, with a range of 161 to 13,266×. Every sample had at least one AML-specific mutation assayed with a coverage depth greater than 5,000×, yielding
a sensitivity of 1 AML cell in ∼2,500 (0.04%). In the remission samples, seven of eight patients demonstrated clearance of all mutations in all samples
tested. In one case (868442), a persistent ancestral clone was detected in all remission samples, harboring a DNMT3AR882H (VAF 10.19% at day 1,152) and
an IRS2D106Y mutation (VAF 12.82% at day 1,152). Mutation clearance of the genes highlighted in red was confirmed with digital droplet PCR, at a sensi-
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(defined by prior exome sequencing), allowing us to restrict our
analysis to genetically defined AML cells (Fig. 2A) (19). Deter-
mination of cell type proportions in these AML cells (Fig. 2B),
and pathways expected to be relevant for chemotherapy sensi-
tivity (i.e., cell cycle, DNA repair, or AraC responsiveness),
revealed no significant differences between the genetically
defined LFR and SFR AML cells (SI Appendix, Fig. S3 C–F and
Dataset S4).
By comparing genetically defined AML cells from LFR vs.
SFR cases using ANOVA, we identified 11,657 differentially
expressed genes (DEGs) (false-discovery rate [FDR] = 0.001,
log fold-change [FC] > ±1) (Fig. 2C and Dataset S5). Func-
tional enrichment analysis showed that morphogenesis, chemo-
taxis, and inflammation pathways were enriched in the genes
that were more highly expressed in the LFR AML cells, while
genes involved in major histocompatibility complex (MHC)
class II-mediated antigen presentation, T cell receptor (TCR)
signaling, and immune responses were expressed at significantly
higher levels in the AML cells from SFR samples (SI Appendix,


























Negative Regulation of Cell Proliferation
Cellular Defense Response
Cellular Protein Metabolic Process
T-cell Co-stimulation
B-cell Receptor Signaling Pathway




































































































































































Fig. 2. RNA-seq studies of LFR and SFR AML samples. (A) UMAP projection of 77,587 genetically defined AML cells from 8 LFR and 7 SFR samples at pre-
sentation, and purified CD34+ cells from the BM samples of 2 healthy donors (HD-CD34). Colors reflect the sample groups, as indicated in the legend. Cells
were identified as AML by requiring expression of a AML-specific somatic mutation in that cell; relevant mutations were defined for each sample by
exome sequencing. (B) Proportion of the genetically defined AML cells composed of different cell types across each AML sample for LFR cases (blue) vs.
SFR cases (red). Horizontal lines indicate median values. (C) DEGs in genetically defined AML cells from the presentation BM samples of SFR vs. LFR
patients. Dashed lines indicate log2 FC of ±2 and FDR < 0.001. Red points represent genes with significantly higher expression in the SFR cases, and blue
points represent genes that are more highly expressed in the LFR cases. (D) Enrichment for gene ontology terms in the DEGs. Blue and red bars are path-
ways enriched in the LFR or SFR cases, respectively; numeric values indicate FDR. (E, Left) Expression of CD200, and MRC1 in single-cell data, with each
point representing a cell. (Center) UMAP plots (split by category) showing single-cell expression of the corresponding gene. (Right) Expression from bulk
RNA-seq datasets with additional AML samples (LFR, blue dots, n = 19; SFR, red dots, n = 31).
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influence MHC class II (20, 21) and HOX gene expression (22,
23), we repeated the ANOVA comparison after restriction to
the NPM1 mutant cases (n = 8 LFR cases, and n = 3 SFR
cases) (Dataset S6). We identified 8,191 DEGs that were
shared with the previous analysis (FDR = 0.001, log FC ± 1)
(SI Appendix, Fig. S4C and Dataset S6). Repeat gene ontology
analysis of the overlapping DEGs eliminated the significance of
HOX gene pathways but increased the significance of the MHC
class II signature found in the SFR AML cells (Fig. 2D and
Dataset S7).
To extend these findings, we evaluated MHC class II gene
expression using bulk RNA-seq data from the 31 SFR vs. 19
LFR cases. We found that CIITA (the master regulator of
MHC class II expression) and several class II genes were
expressed at significantly higher levels in the SFR cases (SI
Appendix, Fig. S4D), even after restricting the comparison to
the cases that did not have NPM1 mutations (SFR n = 13, LFR
n = 4) (SI Appendix, Fig. S4E). The combined data from single-
cell and bulk RNA-seq corroborated the MHC class II pheno-
type, and suggested that NPM1 mutations do not define this
phenotype per se. Two other immunomodulatory genes were
found to be expressed at significantly higher levels in SFR
AML cells: CD200 and MRC1 (Fig. 2E). CD200 has been
reported to be associated with immunosuppression and worse
outcomes in AML (24–26). MRC1 encodes CD206, a marker of
tumor-promoting macrophages in chronic inflammatory dis-
eases (27, 28) and solid tumors (29, 30); it was recently identi-
fied as an independent negative prognostic indicator in AML
(31). The expression differences for CD200 and MRC1 were
similar in the bulk RNA-sequencing data from the extended
sample set (Fig. 2E). The lack of an apparent explanation for
chemotherapy susceptibility in the LFR cases, and the detec-
tion of dysregulated immune-related genes (and genes involved
in resistance to NK/T cell–mediated killing) in SFR cases, sug-
gested that immunomodulatory activities of the tumor microen-
vironment could influence chemotherapy responses in these
cases.
Expression Signatures in Marrow-Infiltrating Immune Cells. We
therefore sought to compare the expression signatures of the
infiltrating immune cells in the leukemic marrow samples. Pop-
ulations of B cells, natural killer cells, regulatory Tcells (Tregs),
and γ/δ Tcells were too small to allow for meaningful studies of
differential gene expression. However, we identified 9,004 T
cells after pooling all samples, shown in the UMAP projection
of Fig. 3A. To identify and label specific T cell subpopulations,
we applied a graph-based clustering approach (Fig. 3B, SI
Appendix, Fig. S5A, and Dataset S8). SFR marrows at presenta-
tion had a smaller proportion of total T cells (SI Appendix, Fig.
S5B). Flow cytometric evaluation of 15 LFR, 26 SFR, and
8 healthy adult donor marrow samples (age range 25 to 40 y)
confirmed that the fraction of CD3+ T cells in SFR AML BM
was significantly lower than that of LFR and healthy donor
marrows (Fig. 3C); specifically, SFR BM samples contained a
significantly smaller fraction of CD4+ T cells (Fig. 3D). Among
the CD4 T cell subsets, the SFR marrow samples had signifi-
cantly fewer Th1 cells, but no statistical differences were
detected in the proportions of Th2, Th17, or Treg cells, which
were all rare populations in these AML samples (Fig. 3E).
We next tested the differential expression of the genes
encoding 143 previously described T cell–specific activation/
exhaustion markers (32, 33) in the total immune cells of SFR
vs. LFR samples. Notably, 57 of the 62 DEGs were expressed
at significantly higher levels in the SFR T cells (Fig. 3F and
Dataset S9). These included genes encoding several putative
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Fig. 3. scRNA-seq and flow cytometric studies of T cells from LFR vs. SFR cases. (A and B) UMAP projections of 9,004 T cells from the total BM samples of
2 healthy donors and the 15 AML patients described in Fig. 2. (A) T cells are colored by the relative expression of LEF1, representing naïve or quiescent
cells (green), vs. GZMA, representing activated or effector cells (red). (B) T cell subsets are labeled by subtypes, identified by applying graph-based cluster-
ing, then identifying enriched biomarkers for each cluster. (C–E) Boxplots displaying flow cytometric data from BM samples from healthy donors (HD) or
LFR vs. SFR cases, for (C) percentages of CD3+ cells, (D) percentages of CD4+ and CD8+ cells, and (E) percentages of Th1, Th2, Th17, and Treg subsets.
Means were analyzed for significance with two-way ANOVA and Tukey correction for multiple comparisons. (F and G) The results of an ANOVA compari-
son of 142 previously described activation/exhaustion markers (32, 33) in all 9,004 T cells (F) and in CD4+ T cells (G), comparing SFR to LFR cases. The x axis
shows the log FC for each gene, with no change (N/C) as the midpoint. The y axis shows FDR in descending values. DEGs (defined by log FC ± 1.3, FDR












Immunosuppression and outcomes in adult patients with de novo acute myeloid
leukemia with normal karyotypes


































inhibitory receptor engaged by MHC class II (log FC = 1.59,
FDR < 0.001), CD38 (log FC = 3.28, FDR < 0.001), and
HAVCR2 (which encodes TIM3; log FC = 1.51, FDR < 0.01),
although the latter was expressed by only a very small number
of T cells (SI Appendix, Fig. S5C). The degree of differential
expression for these genes varied across T cell subpopulations;
for both LAG3 and CD38 it was more prominent in the CD4+
T cell compartment (Fig. 3G) (LAG3, log FC = +2.06, FDR <
0.001; CD38, log FC = +4.58, FDR < 0.001). CD4+ T cells did
not express significant levels of HAVCR2 (SI Appendix, Fig.
S5D and Dataset S10). Other genes encoding potentially rele-
vant immune checkpoint proteins—such as PDCD1, TIGIT,
CTLA4, and CD200R1—were not differentially expressed by
the immune cells of LFR vs. SFR samples (SI Appendix, Fig.
S5D and Dataset S9).
To determine whether the proteins encoded by these
immune checkpoint genes may be relevant for the suppression
of T cell function in AML marrows, we examined the expres-
sion of genes encoding known ligands for these receptors.
MHC class II proteins serve as ligands for LAG3 (34), and as
noted above, many MHC class II genes were more highly
expressed in the SFR AML cells (Fig. 2D and SI Appendix, Fig.
S4 D and E). FGL1, a recently described LAG3 ligand (35),
was not expressed by AML cells (SI Appendix, Fig. S6A). The
gene encoding PECAM1, the ligand for CD38, was expressed
similarly in both LFR and SFR AML cells (SI Appendix, Fig.
S6B). Of the known TIM3 ligands, the gene encoding CEA-
CAM 1 was expressed in only a small fraction of AML cells (SI
Appendix, Fig. S6C), while LGALS9 was more highly expressed
in SFR AML cells (SI Appendix, Fig. S6D) (log FC = +1.3,
FDR < 0.001). Thus, when considering the potential relevance
of immune checkpoint inhibition for relieving Tcell suppression
in NK-AML, LAG3 emerged as a leading candidate because of
its high expression in SFRTcells, and because the genes encod-
ing its major ligands (MHC class II) are highly expressed in the
AML cells of most SFR cases.
T Cell Function in AML BM Samples. We next assessed the ability
of AML cells from cryopreserved LFR and SFR BM samples
to influence the activation of their own infiltrating Tcells over 5
d in vitro, using CD3/CD28 stimulatory beads to activate the
TCR. First, we evaluated unfractionated BM samples from
LFR vs. SFR cases (i.e., containing both AML cells and Tcells)
obtained at presentation. In the presence of AML cells, bead-
activated CD4+ T cells from the LFR cases significantly (P <
0.001) up-regulated the activation markers OX40 and inducible
T cell costimulator, while activation was blunted in the SFR
cases (Fig. 4A and SI Appendix, Fig. S7A, graphs “with AML”).
LFR CD4 Tcells activated the LAG3 marker in the presence of
AML cells (Fig. 4B) (P < 0.001), while SFR cases had higher
baseline percentages of CD4+LAG3+ cells (which corroborated
the scRNA-seq data) that activated less robustly in the presence
of AML cells (Fig. 4B). PD-1 levels increased with T cell stimu-
lation, but there was no significant difference between LFR and
SFR samples (SI Appendix, Fig. S7B). We then tested the acti-
vation potential of CD3+ T cells (purified by bead separation)
from the same BM samples; more than 95% of the AML cells
were removed by this procedure. In the absence of AML cells,
the activation of SFR CD4+ T cells was restored, and LAG3
baseline levels decreased to levels similar to that of LFR sam-
ples (Fig. 4 A and B, “without AML”). CD8+ cells displayed
similar trends (SI Appendix, Fig. S7 C–F), although endogenous
CD8+ T cells suffered disproportionate losses in numbers after
removal of AML cells, making measurements more difficult.
We repeated the 5-d CD3/CD28 bead stimulation protocol
using unfractionated BM samples from presentation (i.e., in the
presence of AML cells), with or without a well-characterized
LAG3 inhibitor known to selectively block the LAG3:MHCII
interaction (clone 17B4) (36–38), or an isotype control anti-
body. With LAG3 inhibition, endogenous CD4+ T cell activa-
tion was restored in most SFR samples to levels that were
similar to that of the LFR samples (Fig. 4C and SI Appendix,
Fig. S7G).
To determine whether these findings were more broadly
applicable, we performed the 5-d T cell stimulation assay using
presentation BM samples from 50 additional de novo AML
patients that were selected based on ELN 2017 classifications
from DNA sequencing and cytogenetics, and on the availability
of high-quality cryovials from presentation BM (see SI
Appendix, Fig. S8 and Dataset S11 for patient characteristics,
mutational profiles, and ELN classifications). The fraction of
activated ( i.e., OX40+) CD4+ T cells before and after stimula-
tion for each sample are shown in Fig. 4D. Activation was
defined as >15% CD4+ OX40+ cells with stimulation, and an
FC from baseline CD4+ OX40 expression ≥2.0, which repre-
sented the median difference in activation (comparing poststi-
mulation over baseline) for the 50 samples tested. Five of 18
(28%) ELN adverse-risk patients exhibited activation; RFS in
these 5 cases was 1.2, 1.4, 4.5, 9.3, and 33.6 mo. None of these
patients was transplanted in first remission. In contrast, 14 of
18 (78%) favorable-risk patients exhibited CD4 activation. The
strong correlation of CD4 activation with these ELN risk
groups suggests that the mutational profile must influence the
immunosuppressive properties of AML cells, and can in fact
supersede them in some adverse-risk cases. For intermediate-
risk cases, 7 of 14 (50%) displayed CD4 activation; importantly,
the “activators” in this risk group had significantly longer RFS
(median survival not yet reached) compared with the nonactiva-
tors (median survival of 250 d, Mantel–Cox log-rank = 0.03)
(Fig. 4E). These data suggest that T cell activation induced by
CD3/28 beads in vitro may provide novel prognostic informa-
tion for the intermediate-risk group that is not detected by the
current, genetically based classifications at presentation. We
performed a multivariate analysis (using Firth logistic regres-
sion) to determine whether any covariate at presentation
(including sex, age at diagnosis, WBC count, BM blast percent-
age, ELN classification, or somatic mutations in AML-
associated genes) was associated with CD4 activation status.
Although ELN favorable-risk patients were 8.2 times more
likely to be CD4 activators, this difference did not reach signifi-
cance due to wide confidence intervals. None of the other
covariates were predictive of CD4+ T cell activation status at
presentation (Dataset S12).
Discussion
By evaluating a group of NK-AML patients with LFRs after che-
motherapy alone, we have been able to identify mechanisms that
may be relevant for AML cell eradication after chemotherapy.
Current prognostic tools, such as the ELN 2017 classification
algorithm, have been especially helpful for guiding therapeutic
decisions for favorable- and adverse-risk patients, but lose some
resolution in the intermediate-risk group, perhaps because these
patients are more genetically heterogenous. The analysis of
remission blood and BM samples from LFR patients revealed
that many do not appear to be living with persistent disease; one
had a persistent ancestral clone, which is a risk factor for the
redevelopment of AML. Since recent studies have shown that
AML relapses often arise from ancestral clones that were pre-
sent at diagnosis (10, 12), these combined observations suggest
that eradication of virtually all AML cells after initial therapy
may be essential for long-term remissions.
Data from this study suggest that an immunosuppressive
phenotype at presentation may negatively influence the effec-
tiveness of standard chemotherapy. Specifically, we showed that
BM samples from LFR patients have well-preserved CD4+ and
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CD8+ T cell populations that can react appropriately to TCR-
mediated activation signals, even in the presence of their own
AML cells. In contrast, SFR AML cells express high levels of
MHC class II, and genes associated with immune suppression.
Their marrows have reduced numbers of immune cells (especially
CD4+ Th1 cells) and their remaining T cells often express an
exhaustion signature (39). Importantly, T cell activation was
blocked in SFR samples by the presence of the AML cells them-
selves, and was reversible in most cases by removing the AML
cells, or blocking the MHC class II inhibitory receptor, LAG3.
Several mechanisms could potentially explain these findings.
For example, the AML cells of SFR cases may express
neoantigen-creating mutations that cause prolonged antigen-
specific T cell activation, and eventual exhaustion (perhaps
because these AML cells have developed mechanisms to resist
T cell–mediated killing). However, using predictive algorithms,
we did not detect substantial differences in putative neoantigen
burdens or human leukocyte antigen (HLA) alleles between
LFR vs. SFR cases (SI Appendix, Fig. S9 and Dataset S13).
However, peptides derived from mutant NPM1 proteins can be
presented by HLA molecules (40) and effectively recognized by
Tcells (41, 42). Since the vast majority of LFR cases had NPM1
mutations (and since CD4+ T cell numbers and activation are
often normal in LFR cases), it is possible that NPM1-specific T
cell responses after chemotherapy may also contribute to the
favorable outcomes of the LFR cases.
Our data also suggest a T cell suppression phenotype in the




Fig. 4. CD4+ T cell activation studies from the BM samples of AML cases at presentation. For the data shown in A–C, cryovials from presentation BM
AML samples from LFR vs. SFR cases were thawed, and the fraction of CD3+ T cells was immediately defined by flow cytometry. These unfractionated sam-
ples were placed in media containing human SCF, IL-3, FLT3L, TPO, and IL-2 (10 ng/mL), and also CD3/CD28 T cell receptor agonist beads in a 1:1 ratio
with the previously defined number of T cells (“with AML”). An identical experiment was performed using BM-derived CD3+ T cells enriched from the
same samples (“without AML”); CD3/CD28 beads were added at a 1:1 ratio after a 24 h “washout” period. T cell activation and inhibition markers were
then quantified by flow cytometry 5 d later in both sets of experiments. The lines show the change in percentage of CD4+ cells expressing the activation
marker OX40 (A) vs. the inhibitory marker LAG3 (B) in samples treated with or without CD3/CD28 beads, which activate via the T cell receptor (as indi-
cated by the legend below each graph). Red lines represent the SFR samples and blue lines represent LFR samples. Two-way ANOVA and Tukey multiple
comparison tests were used to test for significance differences between groups. Results represent the summary of three independent experiments (n = 10
unique samples from both the LFR and SFR sets). (C) Similar levels of activation (as defined by OX40 expression) can be achieved in CD4+ T cells from SFR
samples in the presence of a LAG3 blocking antibody at day 5 poststimulation. The negative controls (I.C. = isotype control) were treated with an isotype
matched antibody. Two-way ANOVA and Tukey multiple comparison tests were used to test for significance differences between groups (n = 15 for LFR
and n = 26 for SFR cases). (D) Changes in T cell activation, measured by the percentage of CD4+ cells expressing OX40, in 50 novel AML cases from an
extension set. Unfractionated BM samples from the presentation samples were evaluated 5 d after activation with CD3/CD28 T cell receptor agonist beads
(in a 1:1 ratio with the number of measured T cells in each sample). The AML samples are grouped according to ELN category. Two-tailed t tests were
used to calculate significance between pre- and postactivation samples. The threshold for CD4+ cell activation was defined as the median difference in
activation (poststimulation over baseline) for the 50 samples tested with this assay (indicated by the black dotted line, at y = 15%). The number of AML
samples that exhibited T cell activation in each ELN risk category, and a statistical comparison of the three groups, are shown below the graphs. Pearson’s
χ2 test with Yates’ continuity correction was used to calculate differences in T cell activators among the groups. (E) The RFS for the intermediate ELN risk
cases from the extension set (D) stratified by CD4+ cell activation status. The blue and red lines represent samples with CD4+ cell activation above and
below the activation threshold (defined as >15% CD4+ OX40+ cells, and an FC from baseline CD4+ OX40 expression ≥2.0). Vertical black lines indicate sub-
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T cell receptors (i.e., checkpoints) by ligands that are expressed
by AML cells. Although inhibition of PD1 and CTLA4 check-
point inhibitors have not yet yielded clinical benefits for AML
patients (43–45), this study suggests that alternative checkpoints
may be relevant. We and others have now identified LAG3,
CD200 (24, 25, 46), and MRC1 (31) as potentially relevant tar-
gets for inhibition in AML. CD200, which is known to suppress
T cell function (25) and directly inhibit NK-cell (47) and Treg
function (24), was significantly overexpressed in SFR cases.
While the Treg and Natural Killer–cell populations in the LFR
and SFR marrow aspirates were small and highly variable, studies
have shown that these cells play a role in AML immune surveil-
lance and responses (48, 49) and they may also contribute to the
immunosuppressive phenotype of SFR cases. The means to
inhibit these pathways currently exist, and are being explored in
preclinical models and early-phase clinical trials (50–52). Addi-
tional mechanisms (e.g., inhibitory chemokines, metabolic inhibi-
tors of T cell function, and others) could also be relevant for this
phenotype, and will need to be further explored.
Previous studies have shown that a dysfunctional CD4+ Tcell
population can dampen immune responses and lead to CD8 T
cell exhaustion (53–57); CD4-depleted tumors have decreased
responsiveness to PD1 inhibition (58, 59) that may in part be
dependent on MHC class II–LAG3 interactions, especially for
tumors with high expression of MHC class II (like SFR AML
cells) (60). Additionally, several groups have reported variable
degrees of T cell dysfunction in the BM samples of AML
patients (61–65), possibly caused by a suppressive effect of
AML cells themselves [shown with AML cell lines (66), and also
with primary AML samples (67)]; here, we demonstrate that the
absence of this immunosuppressive phenotype is strongly corre-
lated with favorable clinical outcomes in both the LFR cases,
and also in many ELN favorable- and intermediate-risk patients.
Among patients with intermediate risk, RFS was significantly
longer in samples with preserved T cell activation. Importantly,
the immune activation phenotype seems to be independent of
other known prognostic factors in AML, such as age and ELN
status.
Remarkably, the concept that well-preserved cell-mediated
immunity can predict responses to chemotherapy in AML patients
(both at diagnosis and during treatment) was proposed 50 y ago
by Freireich and colleagues (15). In that study, AML patients
with impaired delayed type IV hypersensitivity skin testing, and
impaired in vitro T cell responses to mitogens, had higher rates
of chemotherapy induction failure and relapse; interestingly, type
IV reactions are now known to require the function of effector
Th1 cells and macrophages (68), both of which appear to be
altered in the SFR cases.
In summary, the immunological phenotype of LFR patients
strongly suggests that overcoming the immunosuppressive envi-
ronment of “typical” NK-AML cases at presentation (perhaps
by targeting relevant immune checkpoints) could increase the
chances for chemotherapy successes and long remissions. The
ability to integrate immunological phenotype assessment with
current “up-front” risk stratification approaches [for example,
by measuring CD3/CD28-mediated T cell activation in BM
aspirates at presentation or, as Freireich and colleagues (15)
proposed, skin testing for type IV hypersensitivity] may also
prevent unnecessary allotransplantation, with its attendant
complications. Future trials of immunologic modulation for the
therapy of AML should therefore be guided both by the geno-
types and phenotypes of AML cells, and of their immune
microenvironments.
Data Availability. Sequencing data for all patients have been deposited in
dbGaP, https://www.ncbi.nlm.nih.gov/gap/ (phs000159 v.11) (69).
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